TERT promoter methylation is significantly associated with TERT upregulation and disease progression in pituitary adenomas

[1]  H. Wakimoto,et al.  Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas , 2017, Oncotarget.

[2]  W. Stummer,et al.  hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas , 2016, Journal of Neuro-Oncology.

[3]  R. Calado,et al.  Absence of TERT promoter mutations in pituitary adenomas , 2016, Journal of Endocrinological Investigation.

[4]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[5]  Jun S. Song,et al.  Understanding TERT Promoter Mutations: A Common Path to Immortality , 2016, Molecular Cancer Research.

[6]  E. Sahai,et al.  Reactivation of p53 by a Cytoskeletal Sensor to Control the Balance Between DNA Damage and Tumor Dissemination , 2015, Journal of the National Cancer Institute.

[7]  Wei Wang,et al.  Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. , 2015, European journal of cancer.

[8]  G. Kaltsas,et al.  Aggressive Pituitary Tumors , 2015, Neuroendocrinology.

[9]  Antonio Di Ieva,et al.  Aggressive pituitary adenomas—diagnosis and emerging treatments , 2014, Nature Reviews Endocrinology.

[10]  J. Nault,et al.  High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression , 2014, Brain pathology.

[11]  S. Bailey,et al.  TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours , 2014, Acta Neuropathologica.

[12]  K. Ichimura,et al.  TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas , 2013, Acta Neuropathologica.

[13]  David T. W. Jones,et al.  Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system , 2013, Acta Neuropathologica.

[14]  K. Ichimura,et al.  Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss , 2013, Acta Neuropathologica.

[15]  David T. W. Jones,et al.  Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. , 2013, The Lancet. Oncology.

[16]  R. Janzer,et al.  Methylation of the hTERT Promoter: A Novel Cancer Biomarker for Leptomeningeal Metastasis Detection in Cerebrospinal Fluids , 2013, Clinical Cancer Research.

[17]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[18]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[19]  K. Hess,et al.  Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas , 2012, Pituitary.

[20]  K. Mishima,et al.  O6-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment , 2012, Journal of Neuro-Oncology.

[21]  A. Ortíz-Plata,et al.  Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics , 2007, Journal of Neuro-Oncology.

[22]  A. Dobrovic,et al.  Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation , 2007, Nucleic acids research.

[23]  G. Alí,et al.  Telomerase activity and hTERT mRNA expression in glial tumors. , 2006, International journal of oncology.

[24]  Y. Katayama,et al.  Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence , 2003, Journal of Neuro-Oncology.

[25]  F. Bosman,et al.  Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity , 2002, International journal of cancer.

[26]  N. Breslow,et al.  High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. , 1999, Cancer research.

[27]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[28]  W. Stummer,et al.  hTERT promoter methylation in pituitary adenomas , 2015, Brain Tumor Pathology.